Hypoxia in solid tumors is an important predictor of poor clinical outcome to radiotherapy.
Both physicochemical and biological processes contribute to a reduced sensitivity of hypoxic …

The treatment landscape for patients with advanced non-small cell lung cancer has evolved
greatly with the advent of immune checkpoint inhibitors. However, many patients do not …

The main contents of the Clinical Practice Guidelines on Image-Guided Thermal Ablation
(IGTA) of Primary and Metastatic Lung Tumors (2022 Edition) include the following …

Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half
of patients under targeted compounds (TKI) and facilitates use of regional therapies that can …

Although surgical resection with curative intent is the main therapy for both primary and
metastatic lung tumors, about 80% of lung cancers cannot be removed by surgery. Because …

Background Available therapies for castrate-resistant prostate cancer (CRPC) confer
minimal survival advantage; thus, there is interest in metastasis-directed therapy (MDT) for …

Introduction Immune checkpoint inhibitors (ICIs) have changed the management of non-
small cell lung cancer (NSCLC). However, resistance is inevitable. The disease progression …

Introduction Local ablative treatment strategies are frequently offered to patients diagnosed
with oligometastatic disease. Stereotactic body radiotherapy (SBRT), as ablative treatment …

Simple Summary Lung cancer evolutions, innovative systemic treatments, minimally
invasive thoracic surgery approaches and perioperative medical care have changed the role …

Simple Summary Up to 56% of lung cancer patients present with metastatic disease at initial
diagnosis. Whereas these patients were historically deemed incurable, recent evidence …